ERBB2 and neoplasm: Because we found that this particular tumor model spontaneously metastasises more readily than 4T1‐HER2, we were able to assess the capacity of the vaccine to prevent metastatic spread from initial tumor lesions implanted subcutaneously or orthotopically in the mammary tissue.